The Aussie healthcare stock outpacing rivals with near 700% returns
Shares in Australian healthcare firm Avita Medical rose 696% during 2019 and have risen 23% since the start of 2020.
The stock develops and markets regenerative medical products, particularly a spray-on skin used for burns patients known as RECELL which was approved by the US Food & Drug Administration (FDA) in September, 2018.
It was admitted to the ASX 200 in November, 2019 which it said was a “testament to the company’s solid growth trajectory following the commercialisation of the RECELL System combined with the strength of our de-risked pipeline of future indications beyond burns.”.
Its performance compared to returns of 23.4% by the ASX 200 during 2019 and 7.3% since the start of 2020, according to FE Analytics.
In the firm’s half-year results for the six months to 31 December, 2019, the firm said it may have the opportunity to take part in an FDA registration study on vitiligo and would be focusing more on burns and on trauma and soft tissue injuries.
Total revenue for the period was $13.5 million, more than double the $6.9 million reported for the same period in 2018 with the majority of product sales coming from the US after a successful launch of RECELL in January, 2019.
Performance of Avita Medical over the 12 months to 31 December, 2019 versus ASX 200
AUTHOR
Laura Dew
Recommended for you
Platinum Asset Management and VanEck have both announced name changes to multiple of their ETFs to clarify their complexity.
Active ETFs are gaining traction in Asia-Pacific as wealth managers seek to blend the low-cost fees of passive with active management.
Betashares has extended its partnership with platform AMP North to create a targeted geared retirement series utilising internally geared ETFs.
Global X’s third gold-focused ETF in Australia has hit the ASX for financial advisers and investors seeking an alternative way to access the commodity.
